Core Insights - Tourmaline Bio, Inc. will host a virtual Investor Day on December 10, 2024, featuring presentations from its leadership team and Dr. Marc Bonaca, a cardiologist and vascular medicine specialist [1][2] Company Overview - Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with immune and inflammatory diseases [4] - The company's lead asset is pacibekitug (also known as TOUR006), a long-acting, fully-human, anti-IL-6 monoclonal antibody with potential best-in-class properties [5] Product Development - Pacibekitug is being developed for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration [5] - The drug has been studied in approximately 450 participants across six completed clinical trials, indicating a significant level of research and development [5]
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024